

Matthew J Maurer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3289469/publications.pdf>

Version: 2024-02-01

278
papers

11,197
citations

41344

49
h-index

33894

99
g-index

278
all docs

278
docs citations

278
times ranked

14114
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. <i>Blood</i> , 2017, 130, 1800-1808.	1.4	1,084
2	Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5294-5304.	1.6	688
3	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2516-2522.	1.6	610
4	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. <i>Blood</i> , 2014, 124, 1473-1480.	1.4	401
5	Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 2052-2058.	1.6	323
6	Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 1066-1073.	1.6	304
7	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. <i>Journal of Clinical Oncology</i> , 2019, 37, 1790-1799.	1.6	266
8	Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Journal of Clinical Oncology</i> , 2013, 31, 3272-3278.	1.6	259
9	Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the United States: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. <i>American Journal of Hematology</i> , 2015, 90, 790-795.	4.1	221
10	Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma. <i>Cancer</i> , 2008, 113, 508-514.	4.1	220
11	A Prospective Study of Quality of Life in Adults with Newly Diagnosed High-grade Gliomas: The Impact of the Extent of Resection on Quality of Life and Survival. <i>Neurosurgery</i> , 2005, 57, 495-504.	1.1	186
12	Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4191-4198.	1.6	184
13	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1096-1101.	4.1	180
14	The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer. <i>PLoS ONE</i> , 2013, 8, e80063.	2.5	171
15	Tumorgrafts as <i>In Vivo</i> Surrogates for Women with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1288-1297.	7.0	168
16	Prospective Study of Quality of Life in Adults with Newly Diagnosed High-grade Gliomas. <i>Journal of Neuro-Oncology</i> , 2006, 76, 283-291.	2.9	161
17	Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer. <i>Cancer Research</i> , 2015, 75, 22-30.	0.9	157
18	APOBEC3B Upregulation and Genomic Mutation Patterns in Serous Ovarian Carcinoma. <i>Cancer Research</i> , 2013, 73, 7222-7231.	0.9	153

#	ARTICLE	IF	CITATIONS
19	A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2008, 14, 6697-6703.	7.0	149
20	Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. <i>Blood</i> , 2012, 119, 2844-2853.	1.4	149
21	Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3506-3512.	1.6	144
22	Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 144-152.	1.6	142
23	Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 118, 4053-4061.	1.4	136
24	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018, 132, 49-58.	1.4	130
25	Validation of neuroradiologic response assessment in gliomas: Measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods ¹ . <i>Neuro-Oncology</i> , 2006, 8, 156-165.	1.2	117
26	Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 1492-1498.	1.4	110
27	Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. <i>Blood</i> , 2007, 109, 5439-5446.	1.4	109
28	Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes. <i>Clinical Cancer Research</i> , 2017, 23, 3794-3801.	7.0	103
29	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1603-1610.	1.6	93
30	Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. <i>Blood Cancer Journal</i> , 2018, 8, 26.	6.2	92
31	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018, 93, 57-68.	2.8	90
32	Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. <i>Genes Chromosomes and Cancer</i> , 2005, 42, 68-77.	2.8	89
33	Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1123-1132.	6.3	83
34	Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes. <i>Clinical Cancer Research</i> , 2017, 23, 4077-4085.	7.0	80
35	Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. <i>Gynecologic Oncology</i> , 2015, 137, 14-22.	1.4	79
36	Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2010, 28, 412-417.	1.6	75

#	ARTICLE	IF	CITATIONS
37	Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1620-1626.	1.6	70
38	Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma. <i>Cancer</i> , 2010, 116, 2993-3000.	4.1	68
39	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF- κ B positive feedback loop in peripheral T-cell lymphoma. <i>Blood</i> , 2015, 125, 3118-3127.	1.4	68
40	Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. <i>Modern Pathology</i> , 2012, 25, 651-660.	5.5	66
41	Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. <i>Blood</i> , 2008, 112, 2694-2702.	1.4	64
42	Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 6812-6819.	7.0	64
43	Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. <i>Annals of Oncology</i> , 2018, 29, 1822-1827.	1.2	61
44	APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 4746-4755.	7.0	59
45	The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 290-297.	1.3	58
46	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPOR) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1753-1754i.	1.9	57
47	Inherited Determinants of Ovarian Cancer Survival. <i>Clinical Cancer Research</i> , 2010, 16, 995-1007.	7.0	56
48	53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 153, 127-134.	1.4	56
49	Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. <i>Cancer</i> , 2020, 126, 894-907.	4.1	54
50	Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. <i>Blood</i> , 2012, 120, 4400-4406.	1.4	53
51	Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients. <i>Clinical Cancer Research</i> , 2006, 12, 6056-6063.	7.0	52
52	Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangements. <i>Haematologica</i> , 2018, 103, 1899-1907.	3.5	52
53	Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1495-1504.	4.2	51
54	Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, 2821-2826.	1.4	50

#	ARTICLE	IF	CITATIONS
55	Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: A clinic-based case-control study. <i>Cytokine</i> , 2012, 60, 882-889.	3.2	50
56	International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 4019-4026.	1.6	50
57	Complementary and alternative medicine use among long-term lymphoma survivors: A pilot study. <i>American Journal of Hematology</i> , 2009, 84, 795-798.	4.1	49
58	Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.	2.5	49
59	Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. <i>Blood</i> , 2015, 125, 992-998.	1.4	47
60	The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3397-3407.	7.0	45
61	EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review. <i>Genes and Cancer</i> , 2017, 8, 589-599.	1.9	45
62	A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. <i>Cancer</i> , 2006, 107, 2826-2832.	4.1	44
63	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2014, 38, 768-775.	3.7	44
64	Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 1819-1827.	1.6	44
65	PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data. <i>Bioinformatics</i> , 2014, 30, 2678-2680.	4.1	43
66	Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium. <i>Blood</i> , 2019, 134, 763-763.	1.4	42
67	Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. <i>Oncotarget</i> , 2015, 6, 9488-9501.	1.8	42
68	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	4.1	41
69	ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. <i>Haematologica</i> , 2019, 104, e562-e565.	3.5	38
70	Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. <i>Haematologica</i> , 2011, 96, 1619-1626.	3.5	37
71	Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. <i>Blood</i> , 2011, 118, 4882-4889.	1.4	37
72	Elevated pretreatment serum levels of interferon-inducible protein 10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. <i>American Journal of Hematology</i> , 2012, 87, 865-869.	4.1	37

#	ARTICLE	IF	CITATIONS
73	Online Physician Reviews Do Not Reflect Patient Satisfaction Survey Responses. Mayo Clinic Proceedings, 2018, 93, 453-457.	3.0	37
74	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer Journal, 2019, 9, 73.	6.2	37
75	Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. American Journal of Hematology, 2012, 87, 880-885.	4.1	36
76	Elevated soluble IL-2R^{\pm} , IL-8 , and MIP-1^2 levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma. American Journal of Hematology, 2014, 89, E223-7.	4.1	36
77	Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. Blood Cancer Journal, 2018, 8, 97.	6.2	36
78	Utility of Progranulin and Serum Leukocyte Protease Inhibitor as Diagnostic and Prognostic Biomarkers in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1730-1735.	2.5	33
79	A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and ^{90}Y trium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. American Journal of Hematology, 2013, 88, 589-593.	4.1	33
80	Plasma immune analytes in patients with epithelial ovarian cancer. Cytokine, 2015, 73, 108-113.	3.2	31
81	Transthoracic Echocardiography versus Computed Tomography for Ascending Aortic Measurements in Patients with Bicuspid Aortic Valve. Journal of the American Society of Echocardiography, 2017, 30, 625-635.	2.8	31
82	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL). Blood, 2007, 110, 121-121.	1.4	31
83	Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. American Journal of Hematology, 2011, 86, 998-1000.	4.1	28
84	CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. Cancer Immunology, Immunotherapy, 2013, 62, 1475-1484.	4.2	28
85	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia, 2021, 35, 522-533.	7.2	28
86	Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. British Journal of Haematology, 2019, 184, 524-535.	2.5	27
87	Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. American Journal of Hematology, 2014, 89, 639-645.	4.1	26
88	History of autoimmune conditions and lymphoma prognosis. Blood Cancer Journal, 2018, 8, 73.	6.2	26
89	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. Blood, 2019, 134, 1289-1297.	1.4	26
90	Aortic Stenosis Progression, Cardiac Damage, and Survival. JACC: Cardiovascular Imaging, 2021, 14, 1113-1126.	5.3	26

#	ARTICLE	IF	CITATIONS
91	Cardiac Outcomes in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. <i>Blood</i> , 2011, 118, 2656-2656.	1.4	26
92	Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 3930-3937.	1.6	24
93	Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. <i>Blood Advances</i> , 2021, 5, 2426-2437.	5.2	24
94	Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. <i>Lancet Haematology</i> , 2022, 9, e289-e300.	4.6	24
95	Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 752-758.	4.1	23
96	Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. <i>Oncotarget</i> , 2015, 6, 35737-35754.	1.8	23
97	Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma. <i>Blood Cancer Journal</i> , 2018, 8, 110.	6.2	22
98	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2020, 71, 1221-1228.	5.8	22
99	High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?. <i>Blood Cancer Journal</i> , 2020, 10, 5.	6.2	22
100	18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of "indeterminate" reports. <i>Leukemia and Lymphoma</i> , 2010, 51, 439-446.	1.3	21
101	Large-Scale Evaluation of Common Variation in Regulatory T Cell-Related Genes and Ovarian Cancer Outcome. <i>Cancer Immunology Research</i> , 2014, 2, 332-340.	3.4	21
102	Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group trial. <i>Investigational New Drugs</i> , 2005, 23, 495-503.	2.6	20
103	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. <i>British Journal of Haematology</i> , 2018, 182, 644-653.	2.5	20
104	Inherited Variants in Regulatory T Cell Genes and Outcome of Ovarian Cancer. <i>PLoS ONE</i> , 2013, 8, e53903.	2.5	20
105	A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma. <i>Cancer</i> , 2008, 112, 1772-1779.	4.1	19
106	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. <i>American Journal of Hematology</i> , 2019, 94, 658-666.	4.1	19
107	Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 417-422.	4.1	18
108	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. <i>Blood Cancer Journal</i> , 2020, 10, 117.	6.2	18

#	ARTICLE	IF	CITATIONS
109	Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: <sc>CALGB</sc>/Alliance 50403. American Journal of Hematology, 2020, 95, 583-593.	4.1	18
110	Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. Haematologica, 2018, 103, 297-303.	3.5	17
111	An HLA-DRâ€“Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2â€“Specific Immunity in Patients with Cancer. Cancer Research, 2008, 68, 4893-4901.	0.9	16
112	Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts. Cytokine, 2013, 64, 523-531.	3.2	16
113	Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in Bâ€“and Tâ€“cell nonâ€“H<sc>odgkin lymphoma. American Journal of Hematology, 2014, 89, 1116-1120.	4.1	16
114	The association of physical activity before and after lymphoma diagnosis with survival outcomes. American Journal of Hematology, 2018, 93, 1543-1550.	4.1	16
115	Impact of Organ Functionâ€“Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. Journal of Clinical Oncology, 2021, 39, 1641-1649.	1.6	16
116	A Degenerate HLA-DR Epitope Pool of HER-2/neu Reveals a Novel In vivo Immunodominant Epitope, HER-2/neu88-102. Clinical Cancer Research, 2010, 16, 825-834.	7.0	15
117	Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic. Gynecologic Oncology, 2015, 137, 77-85.	1.4	15
118	Detection of extranodal and spleen involvement by FDGâ€“PET imaging predicts adverse survival in untreated follicular lymphoma. American Journal of Hematology, 2019, 94, 786-793.	4.1	15
119	Comparison of the NCCNâ€“IPI, the IPI and PIT scores as prognostic tools in peripheral Tâ€“cell lymphomas. British Journal of Haematology, 2019, 186, e24-e27.	2.5	15
120	Prevalence, clinical characteristics and prognosis of EBVâ€“positive follicular lymphoma. American Journal of Hematology, 2019, 94, E62-E64.	4.1	15
121	Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium. Blood, 2021, 138, 744-744.	1.4	15
122	Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors. Leukemia and Lymphoma, 2015, 56, 434-439.	1.3	14
123	Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia. American Journal of Hematology, 2016, 91, 776-781.	4.1	14
124	High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients. Blood, 2021, 138, 181-181.	1.4	14
125	Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): Results of North Central Cancer Treatment Group trial 98-72-51. International Journal of Radiation Oncology Biology Physics, 2005, 61, 380-386.	0.8	13
126	Inherited genetic variation and overall survival following follicular lymphoma. American Journal of Hematology, 2012, 87, 724-726.	4.1	13

#	ARTICLE	IF	CITATIONS
127	A susceptibility locus for classical Hodgkin lymphoma at 8q24 near <i>MYC</i> predicts patient outcome in two independent cohorts. <i>British Journal of Haematology</i> , 2018, 180, 286-290.	2.5	13
128	Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. <i>Hematological Oncology</i> , 2018, 36, 749-756.	1.7	13
129	Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 161-171.	4.2	12
130	Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 820-828.	2.5	12
131	Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent. <i>Blood</i> , 2020, 135, 1008-1018.	1.4	12
132	Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. <i>British Journal of Haematology</i> , 2020, 189, 661-671.	2.5	12
133	Variability of performance status assessment between patients with hematologic malignancies and their physicians. <i>Leukemia and Lymphoma</i> , 2018, 59, 695-701.	1.3	11
134	Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma – tissue remains the issue. <i>Leukemia and Lymphoma</i> , 2017, 58, 2342-2348.	1.3	10
135	Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 520-529.	1.4	10
136	Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. <i>American Journal of Surgical Pathology</i> , 2021, 45, 384-393.	3.7	10
137	<i>FCGR3A</i> polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017, 35, 447-455.	1.7	9
138	Association of elevated serum free light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <i>Blood Cancer Journal</i> , 2019, 9, 59.	6.2	9
139	Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting. <i>Scientific Reports</i> , 2021, 11, 8076.	3.3	9
140	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2019, 134, 69-69.	1.4	9
141	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. <i>Blood Advances</i> , 2022, 6, 1350-1360.	5.2	9
142	Expression of LMO2 Is Associated With t(14;18)/IGH-BCL2 Fusion but Not BCL6 Translocations in Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2010, 134, 278-281.	0.7	8
143	Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab. <i>American Journal of Hematology</i> , 2017, 92, 1156-1162.	4.1	8
144	Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors. <i>Leukemia and Lymphoma</i> , 2021, 62, 247-251.	1.3	8

#	ARTICLE	IF	CITATIONS
145	Relapsed/Refractory International Prognostic Index (R ² -IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. American Journal of Hematology, 2021, 96, 599-605.	4.1	8
146	Cardiac Scintigraphy and Screening for Transthyretin Cardiac Amyloidosis. Circulation, 2021, 144, 1005-1007.	1.6	8
147	FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status. Leukemia and Lymphoma, 2013, 54, 2571-2573.	1.3	7
148	Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma. Oncologist, 2020, 25, 689-695.	3.7	7
149	Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. HemaSphere, 2021, 5, e640.	2.7	7
150	Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. International Journal of Molecular Epidemiology and Genetics, 2011, 2, 245-52.	0.4	7
151	Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials. Blood Cancer Journal, 2022, 12, 1.	6.2	7
152	Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A. PLoS ONE, 2019, 14, e0224564.	2.5	6
153	The association of health behaviors with quality of life in lymphoma survivors. Leukemia and Lymphoma, 2021, 62, 271-280.	1.3	6
154	Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. Cancer, 2021, 127, 3390-3402.	4.1	6
155	Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance). Blood, 2018, 132, 146-146.	1.4	6
156	Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy. Blood, 2015, 126, 2683-2683.	1.4	6
157	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-Cell Lymphomas: A North American PTCL Study Group Project. Blood, 2012, 120, 1545-1545.	1.4	6
158	Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009038.	3.9	6
159	LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. Leukemia and Lymphoma, 2012, 53, 1105-1112.	1.3	5
160	Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. British Journal of Haematology, 2018, 183, 149-152.	2.5	5
161	Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy. Clinical Epidemiology, 2019, Volume 11, 987-996.	3.0	5
162	Compliance with cancer screening and influenza vaccination guidelines in non-Hodgkin lymphoma survivors. Journal of Cancer Survivorship, 2020, 14, 316-321.	2.9	5

#	ARTICLE	IF	CITATIONS
163	Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. American Journal of Hematology, 2021, 96, 979-988.	4.1	5
164	Body mass index and survival of patients with lymphoma. Leukemia and Lymphoma, 2021, 62, 2671-2678.	1.3	5
165	PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.. Blood, 2009, 114, 137-137.	1.4	5
166	In-Vivo Activation Of STAT3 In Angioimmunoblastic T Cell Lymphoma, PTCL Not Otherwise Specified, and ALK Negative Anaplastic Large Cell Lymphoma: Implications For Therapy. Blood, 2013, 122, 844-844.	1.4	5
167	Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. Blood, 2016, 128, 3027-3027.	1.4	5
168	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. Blood, 2016, 128, 3034-3034.	1.4	5
169	Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 3035-3035.	1.4	5
170	Cardiovascular Diseases That Have Emerged From the Darkness. Journal of the American Heart Association, 2021, 10, e021095.	3.7	5
171	Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?. Nutrition and Cancer, 2018, 70, 1088-1090.	2.0	4
172	POD24 in MZL: a means to an end or an end point in itself?. Blood, 2019, 134, 787-788.	1.4	4
173	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. Blood Cancer Journal, 2021, 11, 133.	6.2	4
174	Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD). Blood, 2018, 132, 456-456.	1.4	4
175	Changes in Quality of Life in Indolent Non-Hodgkin Lymphoma 3 Years after Diagnosis. Blood, 2017, 130, 917-917.	1.4	4
176	Germline Variation in Complement Genes and Event-Free Survival in Follicular Lymphoma.. Blood, 2009, 114, 440-440.	1.4	4
177	Testicular ^{FDC}PET</sup>/^{CT} uptake threshold in aggressive lymphomas. American Journal of Hematology, 2021, 96, E81-E83.	4.1	3
178	JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis. Blood Cancer Journal, 2021, 11, 56.	6.2	3
179	Association of Health Behaviors and Quality of Life in Lymphoma Survivors. Blood, 2018, 132, 4838-4838.	1.4	3
180	Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant. Blood, 2021, 138, 878-878.	1.4	3

#	ARTICLE	IF	CITATIONS
181	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. <i>Blood</i> , 2021, 138, 2527-2527.	1.4	3
182	Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. <i>Blood Advances</i> , 2022, 6, 2745-2756.	5.2	3
183	Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC). <i>Blood</i> , 2019, 134, 400-400.	1.4	2
184	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019, 134, 72-72.	1.4	2
185	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. <i>Blood</i> , 2020, 136, 7-8.	1.4	2
186	Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010, 116, 996-996.	1.4	2
187	Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population. <i>Blood</i> , 2012, 120, 1540-1540.	1.4	2
188	IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era. <i>Blood</i> , 2013, 122, 362-362.	1.4	2
189	Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements". <i>Blood</i> , 2016, 128, 1750-1750.	1.4	2
190	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1874-1874.	1.4	2
191	QOL at 3 years after diagnosis in aggressive lymphoma survivors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9586-9586.	1.6	2
192	A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2007, 110, 124-124.	1.4	2
193	Whole-Exome Analysis Of DLBCL Tumors Reveals a Unique Genetic Signature Associated With Aggressive Disease. <i>Blood</i> , 2013, 122, 499-499.	1.4	2
194	Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 2896-2896.	1.4	2
195	Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. <i>Blood Advances</i> , 2022, 6, 5210-5221.	5.2	2
196	Survival Prediction Based on Inherited Gene Variation Analysis. <i>Methods in Molecular Biology</i> , 2013, 1049, 53-64.	0.9	1
197	The potential of serum light chains in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1857-1858.	1.3	1
198	Host genetic variation in tumor necrosis factor and nuclear factor- κ B pathways and overall survival in mantle cell lymphoma: A discovery and replication study. <i>American Journal of Hematology</i> , 2019, 94, E153-E155.	4.1	1

#	ARTICLE	IF	CITATIONS
199	Prognostic impact of depth of response in Waldenström macroglobulinemia patients treated with fixed duration chemoimmunotherapy.. Journal of Clinical Oncology, 2021, 39, 8049-8049.	1.6	1
200	Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2021, 39, e13569-e13569.	1.6	1
201	Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. Blood, 2018, 132, 454-454.	1.4	1
202	Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL. Blood, 2018, 132, 4204-4204.	1.4	1
203	Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource. Blood, 2012, 120, 1546-1546.	1.4	1
204	Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era. Blood, 2015, 126, 3992-3992.	1.4	1
205	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. Blood, 2016, 128, 1104-1104.	1.4	1
206	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). Blood, 2016, 128, 155-155.	1.4	1
207	Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. Blood, 2016, 128, 5299-5299.	1.4	1
208	Prevalence and clinical correlates of vulnerable status using the Vulnerable Elders Survey 13 (VES-13) in newly diagnosed adult non-Hodgkin lymphoma (NHL) patients: A LEO cross-sectional analysis.. Journal of Clinical Oncology, 2018, 36, 10042-10042.	1.6	1
209	Polymorphisms in One-Carbon Metabolism Genes and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL).. Blood, 2007, 110, 1568-1568.	1.4	1
210	Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients. Blood, 2010, 116, 991-991.	1.4	1
211	Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients. Blood, 2011, 118, 429-429.	1.4	1
212	EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (âˆ’) Counterparts: Results From University of Iowa/Mayo Clinic SPORE. Blood, 2012, 120, 1604-1604.	1.4	1
213	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. Blood, 2013, 122, 76-76.	1.4	1
214	Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas. Blood, 2018, 132, 5401-5401.	1.4	1
215	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients â‰¥65 Years Receiving Bendamustine-Rituximab. Blood, 2021, 138, 3517-3517.	1.4	1
216	Vaccination History and Risk of Lymphoma and Its Major Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0383.2021.	2.5	1

#	ARTICLE	IF	CITATIONS
217	The Impact of Trial Eligibility Criteria on Outcomes in a Nationwide Cohort of Newly Diagnosed DLBCL Patients Treated with R-CHOP. Blood, 2021, 138, 53-53.	1.4	1
218	Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. Blood, 2021, 138, 2429-2429.	1.4	1
219	Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium. Blood, 2021, 138, 3527-3527.	1.4	1
220	Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes. Blood, 2021, 138, 2524-2524.	1.4	1
221	Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis. Blood, 2020, 136, 35-36.	1.4	1
222	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 26-27.	1.4	1
223	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. Blood Cancer Journal, 2022, 12, 78.	6.2	1
224	Reply to J.R. Carver et al. Journal of Clinical Oncology, 2010, 28, e612-e612.	1.6	0
225	Reply to C. Barker et al and H. Asai et al. Journal of Clinical Oncology, 2010, 28, e427-e428.	1.6	0
226	Clinical trials in lymphoma. , 0, , 45-60.		0
227	Reply to the letter to the editor "Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting" by van der Gali"n et al.. Annals of Oncology, 2019, 30, 153.	1.2	0
228	The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma. Haematologica, 2021, 106, 2261-2264.	3.5	0
229	Reversing the restrictive trend in diffuse large B-cell lymphoma trial eligibility: it's time to open the gates!. British Journal of Haematology, 2021, 193, 697-698.	2.5	0
230	Germline Single Nucleotide Polymorphisms (SNPs) in IL1A, IL6, IL10, and IFNGR2 in Combination with Clinical with Demographic Factors Predict Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL).. Blood, 2006, 108, 2028-2028.	1.4	0
231	Smoking, Obesity and Overall Survival in Non-Hodgkin Lymphoma (NHL): A Population-Based Study.. Blood, 2006, 108, 4649-4649.	1.4	0
232	Cytokine Gene Polymorphisms and Overall Survival in Follicular Lymphoma: Results from a Large Population-Based Study.. Blood, 2006, 108, 820-820.	1.4	0
233	Host Immunogenetic Single Nucleotide Polymorphisms (SNPs) Predict Overall Survival in Small Lymphocytic Lymphoma.. Blood, 2006, 108, 2396-2396.	1.4	0
234	Host Genetic Variation in the Cell Cycle and NF-ÎB Pathways and Overall Survival in Mantle Cell Lymphoma.. Blood, 2007, 110, 1582-1582.	1.4	0

#	ARTICLE	IF	CITATIONS
235	Vitamin D Deficiency Is Associated with Inferior Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma.. Blood, 2009, 114, 1952-1952.	1.4	0
236	MYC Translocations Are Associated with Poor Overall Survival in DLBCL Patients in Both the Chemotherapy and Immunochemotherapy Eras.. Blood, 2009, 114, 443-443.	1.4	0
237	Elevated Serum IL-10 Levels in Patients with Diffuse Large B Cell Lymphoma: A Mechanism of Aberrant JAK2 Kinase Activation. Blood, 2011, 118, 960-960.	1.4	0
238	Elevated Monoclonal Free Light Chains Are a Serum Marker of ABC Type Diffuse Large B-Cell Lymphoma. Blood, 2011, 118, 1591-1591.	1.4	0
239	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Blood, 2012, 120, 684-684.	1.4	0
240	Expression of MYC but Not pSTAT3 Is an Adverse Prognostic Factor for Diffuse Large B Cell Lymphoma (DLBCL) Treated with Epratuzumab/R-CHOP. Blood, 2012, 120, 1575-1575.	1.4	0
241	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. Blood, 2012, 120, 149-149.	1.4	0
242	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. Blood, 2012, 120, 1563-1563.	1.4	0
243	Host Genetics and Risk of Cardiovascular Disease in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. Blood, 2012, 120, 1573-1573.	1.4	0
244	Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes.. Blood, 2012, 120, 2655-2655.	1.4	0
245	Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies. Blood, 2012, 120, 3637-3637.	1.4	0
246	CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. Blood, 2012, 120, 2702-2702.	1.4	0
247	Elevated Soluble IL-2Ra Levels Are Associated With Inferior Outcome and Is Independent Of MIPI Score in Patients With Mantle Cell Lymphoma. Blood, 2013, 122, 4256-4256.	1.4	0
248	Variability Of Performance Status Assessment Between Patients With Hematologic Malignancies and Their Physicians. Blood, 2013, 122, 1703-1703.	1.4	0
249	Tumor Monocyte Cross Talk Promotes Chemotherapy Resistance In Lymphoma. Blood, 2013, 122, 1774-1774.	1.4	0
250	Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 131-131.	1.4	0
251	Tissue Is the Issue: Accuracy of PET Imaging to Detect Bone Marrow Clearance in Patients with Peripheral T-Cell Lymphoma. Blood, 2015, 126, 3947-3947.	1.4	0
252	Lymphocyte-to-Monocyte Ratio at Diagnosis and Survival in De Novo Double/Triple Hit Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 3885-3885.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma. Blood, 2015, 126, 1501-1501.	1.4	0
254	Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era. Blood, 2015, 126, 1456-1456.	1.4	0
255	Outcomes of DLBCL Patients Entering Surveillance (without maintenance) after Immunochemotherapy in a Large Observational Study. Blood, 2016, 128, 3036-3036.	1.4	0
256	An International Assessment of Event-Free Survival at 24 Months (EFS24) and Subsequent Survival in Peripheral T-Cell Lymphoma. Blood, 2016, 128, 920-920.	1.4	0
257	No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era. Blood, 2016, 128, 107-107.	1.4	0
258	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 2935-2935.	1.4	0
259	Compliance with Age-Appropriate Screening for Malignancies and Influenza Vaccination in 3-Year Lymphoma Survivors. Blood, 2018, 132, 4791-4791.	1.4	0
260	Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. Blood, 2018, 132, 2979-2979.	1.4	0
261	Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era. Blood, 2018, 132, 4140-4140.	1.4	0
262	Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients. Blood, 2019, 134, 5215-5215.	1.4	0
263	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Blood, 2019, 134, 919-919.	1.4	0
264	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. Blood, 2019, 134, 923-923.	1.4	0
265	Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era. Blood, 2019, 134, 422-422.	1.4	0
266	Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments. Blood, 2021, 138, 1327-1327.	1.4	0
267	Mismatch-Repair Deficiency in Follicular Lymphoma Tumors Is Common and Associated with a Favorable Overall Survival. Blood, 2021, 138, 3523-3523.	1.4	0
268	CHFR and Paclitaxel Sensitivity of Ovarian Cancer. Cancers, 2021, 13, 6043.	3.7	0
269	Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis. Blood, 2021, 138, 338-338.	1.4	0
270	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. Blood, 2021, 138, 2508-2508.	1.4	0

#	ARTICLE	IF	CITATIONS
271	Integration of Tumor Transcriptomic, Genomic, and Immune Profiles Reveals Distinct Populations of Low-Grade B-Cell Lymphomas with Poor Outcome. Blood, 2021, 138, 808-808.	1.4	0
272	Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. Blood, 2020, 136, 21-22.	1.4	0
273	Body Mass Index and Survival of Patients with Lymphoma. Blood, 2020, 136, 2-3.	1.4	0
274	Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. Blood, 2020, 136, 36-37.	1.4	0
275	The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma. Blood, 2020, 136, 39-40.	1.4	0
276	Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas. Blood, 2020, 136, 15-16.	1.4	0
277	Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis. JCO Oncology Practice, 0, , .	2.9	0
278	Therapy for patients with POD24 follicular lymphoma: Treatment patterns and outcomes from the Lymphoma Epidemiology of Outcomes (LEO) Consortium.. Journal of Clinical Oncology, 2022, 40, 7573-7573.	1.6	0